Together, these findings confirm that peptides synthesised with D-enantiomer amino acids such as R18D, unlike peptides synthesised with L-enantiomer amino acids are highly resistant to proteolytic degradation and are likely to retain their neuroprotective efficacy when co-administered with tPA/TNK thrombolysis in ischaemic stroke. This evidence concerns the gene PLAT and ischemic stroke.